Program
NNC0442-0344
A development code. Also written as “NNC0442-0344 A”.
Its studies are mostly in Hemophilia A, led by Novo Nordisk.
Furthest: phase 1, since Oct 14, 20243 company-led studies, 1 open or runningNext primary completion: Feb 5, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordisk | 31 open or running | phase 1since Oct 14, 2024 | Oct 14, 2024 | Feb 5, 2027phase 1 · NCT07220564 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 14, 2024First study: phase 1 study in Hemophilia AFirst studyNCT06649630 · 95 enrolled · Germany
- Oct 22, 2025Phase 1 study in Hemophilia ANCT07220564 · 30 planned · United States, Austria, Belgium and more
- Nov 16, 2025Phase 1 study in Hemophilia ANCT07238816 · 80 enrolled · United States
Ahead
- Feb 5, 2027Primary completion: phase 1 study in Hemophilia ANCT07220564
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07238816Hemophilia A · United States | 1 | Completed | May 8, 2026 | 80 |
| NCT07220564Hemophilia A · United States, Austria, Belgium and more | 1 | Recruiting | Feb 5, 2027 | 30 |
| NCT06649630Hemophilia A · Germany | 1 | Completed | Mar 26, 2026 | 95 |
How it is read
Names in the registry
- “NNC0442-0344 A”, 3 entries
Codes read as this program: NNC04420344.
Conditions, from the studies’ own filings
- Hemophilia A, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.